Expression of interferon-alpha receptor mRNA in the liver in chronic liver diseases associated with hepatitis C virus: Relation to effectiveness of interferon therapy
- 30 Downloads
To investigate whether interferon-alpha receptor (IFN-αRc) expression was related to the effectiveness of interferon therapy in hepatitis C virus (HCV)-associated chronic liver disease (CLD), IFN-αRc mRNA was investigated by reverse transcription polymerase chain reaction (RT-PCR) in liver biopsies and peripheral blood mononuclear cells (PBMCs) from 40 patients with HCV-associated CLD who subsequently received IFN-α therapy. IFN-αRc mRNA in the liver was detected in 18 of 20 (90%) responders to IFN and in 5 of 20 (25%) non-responders (P<0.01). In PBMCs, IFN-αRc mRNA was detected in all patients regardless of response to IFN. Increased histological hepatitis activity and liver fibrosis were significantly related to the absence of IFN-αRc mRNA. The HCV-RNA genotype showed no significant relationship to IFN-αRc mRNA expression. Our results suggest that IFN-αRc mRNA expression in the liver, but not in PBMCs, is closely associated with the effectiveness of IFN-α therapy in HCV-associated CLD.
Key wordsChronic hepatitis C interferon-α receptor mRNA interferon therapy
Unable to display preview. Download preview PDF.
- 3.Yoshida K, Kakumu S, Wakita T, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha: Relationship to genotype of hepatitis C virus. Hepatology 1992;14:35–40.Google Scholar
- 10.Velazquez L, Fellous M, Stark GR, Pellegrini S. A protein kinase in the interferon alpha/beta signaling pathway. Cell 1992;24:313–322.Google Scholar
- 11.De Maeyer E, De Maeyer-Guignand J. Interferon receptor. In: De Maeyere E, De Maeyer-Guignand J (eds) Interferon and other revelatory cytokines. New York: John Wiley and Sons, 1988;91–113.Google Scholar
- 13.Gallo-Rayet N, Escher E. Adrenocorticotropin receptors in rat adrenal glomerulosa cells. Endocrinology 1985;117:38–46.Google Scholar
- 16.De Maeyer E, De Maeyer-Guignand J. Production of IFN-γ by T cells and modulation of T cell, B cell, and NK cell activity by interferons. In: De Maeyere E, De Maeyer-Guignand J (eds) Interferon and other revelatory cytokines. New York: John Wiley and Sons, 1988;221–273.Google Scholar
- 19.Karino Y, Hige S, Sasaki Y, Tsuyuguchi M, Matsushima T, Miyazaki T, Okuuchi Y, Toyota J. Relationship between serum 2-5AS activity and the reduction of HCV-RNA during interferon therapy. In: Nishioka K, Suzuki H, Mishiro S, Oda K (eds). Viral hepatitis and liver disease. Tokyo New York Berlin Heidelberg: Springer, 1994;631–634.Google Scholar
- 20.Fukuda R, Satoh S, Nguyen TX, et al. Expression of cytokine mRNA in the liver of chronic hepatitis C: Comparison with chronic hepatitis B. J Gastroenterol 1995;31:41–47.Google Scholar
- 23.Degroote J, Desmet VJ, Gedigk P, et al. A classification of chronic hepatitis. Lancet 1968;II:626–628.Google Scholar
- 25.De Maeyer E, De Maeyer-Guignand J. The antiviral activity of interferon. In: De Maeyere E, De Maeyer-Guignand J (eds) Interferon and other revelatory cytokines. New York: John Wiley, Sons, 1988;115–133.Google Scholar
- 33.Auguet M, Gresser I, Hovanessian AG, et al. Specific high-affinity binding of125I-labeled mouse interferon to interferon-resistant embryonal carcinoma cells in vitro. Virology 1981;114:585–588.Google Scholar
- 37.Lörh HF, Schlaak JF, Gerken G, et al. Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T lymphocytes from patients with chronic hepatitis of different etiology. Liver 1994;14:161–166.Google Scholar